Psoriasis Gut Biotics May Ease Skin Inflammation
A review of small randomized trials suggests probiotics, prebiotics, synbiotics, and postbiotics may help reduce psoriasis severity as add-on care, but evidence is not strong enough
Biotics may support psoriasis care by shifting the gut microbiome and lowering inflammatory signals linked to skin disease. In a recent review, randomized trials reported improvements in gut bacteria, inflammatory markers such as CRP, TNF, IL-6, IL-1β, LPS, and IL-17, and psoriasis severity scores.
The signal is promising, but the evidence remains early because the trials were small, varied, and not yet definitive.
Study Details
Psoriasis is not just a skin condition. It is a chronic immune-mediated inflammatory disease that can involve systemic inflammation, metabolic risk, joint disease, and quality-of-life burden. Researchers are increasingly studying the gut-skin axis, the idea that intestinal microbes, gut barrier function, and immune regulation may influence inflammatory skin diseases such as psoriasis.
The Medscape Europe report summarized a review published in Nutrition Reviews that evaluated whether biotics could serve as an adjunctive therapy for psoriasis. The interventions included probiotics, prebiotics, synbiotics, and postbiotics. These approaches are not intended to replace topical therapy, phototherapy, systemic agents, or biologics, but they may become part of a broader supportive strategy for selected patients.
For patients, the practical message is simple: gut health may matter in psoriasis, but supplements are not a cure. For clinicians, the more important question is whether future trials can identify which formulations, doses, durations, and patient phenotypes are most likely to respond.
Methodology
The review included randomized controlled trials published between 2013 and 2024 that tested biotic interventions in people with psoriasis. Most studies evaluated lactic acid bacteria, especially Lactobacillus and Bifidobacterium species, often paired with prebiotic fibers such as inulin or oligosaccharides.
The studies looked at changes in gut microbiota, inflammatory biomarkers, and clinical severity. Psoriasis severity was commonly assessed using PASI, the Psoriasis Area and Severity Index. This score helps quantify how much skin is affected and how inflamed, thickened, and scaly the plaques are.
Key Findings
Some formulations increased beneficial gut bacteria, including Lactobacillus species and Parabacteroides species.
Several trials reported lower inflammatory markers, including CRP, TNF, IL-6, IL-1β, LPS, and IL-17. These markers are relevant because psoriasis is driven by immune activation, not just surface-level skin irritation.
Clinical severity often improved, with reductions in PASI scores reported after several weeks of supplementation. A recent umbrella review also found that probiotics were associated with reduced PASI scores, higher PASI 75 response rates, lower inflammatory biomarkers, and improved Dermatology Life Quality Index scores.
One notable trial used heat-inactivated Prevotella histicola, suggesting that even nonviable bacteria or bacterial components may have immune effects. This supports growing interest in postbiotics, not only live probiotics.
The biggest limitation is evidence quality. The Medscape summary noted that only 10 randomized controlled trials met the review criteria, each enrolling fewer than 30 participants, with different protocols, formulations, and outcome measures.
Implications for Practice
For patients, biotics should be viewed as a possible add-on, not a replacement for prescribed psoriasis therapy. Someone with mild psoriasis may be interested in discussing probiotic or fiber-based strategies with their clinician. Someone with moderate to severe disease, psoriatic arthritis, extensive plaques, nail disease, or major quality-of-life impairment should not delay proven treatments while trying supplements.
For healthcare providers, this review strengthens the rationale for discussing diet, fiber intake, metabolic health, and gut health as part of psoriasis care. The most defensible clinical position today is cautious integration: encourage a high-fiber, metabolically healthy dietary pattern, consider biotics in selected patients, and avoid promising disease control from supplements alone.
The next step is precision. Future trials need larger sample sizes, standardized formulations, longer follow-up, and biomarker-driven patient selection. Key unanswered questions include which psoriasis phenotypes respond best, whether response differs in patients with obesity or metabolic syndrome, and whether microbiome patterns can predict benefit.
Bottom Line
Biotics may help some people with psoriasis by improving gut microbial balance and reducing immune inflammation. The current evidence is encouraging but not practice-changing on its own. Patients should see this as a supportive option to discuss with their dermatologist, while clinicians should see it as a signal that the gut-skin axis deserves more rigorous study.